Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial
E. Antonio Chiocca, scientists from Harvard Medical School and his teams research about interleukin-12 gene therapy in patients was published recently on Science Translational Medcines. The antitumor cytokine interleukin-12 cannot be used as a systemic treatment because of excessive toxicity.
Date：2019-09-17
